{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:10:12Z","timestamp":1790122212943,"version":"4.0.1"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"suppl_6","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharmaceuticals UK"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1093\/rheumatology\/key217","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T03:32:47Z","timestamp":1530761567000},"page":"vi10-vi17","source":"Crossref","is-referenced-by-count":22,"title":["The current standard of care and the unmet needs for axial spondyloarthritis"],"prefix":"10.1093","volume":"57","author":[{"given":"Basil","family":"Noureldin","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Royal Shrewsbury Hospital, Shrewsbury"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Barkham","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, New Cross Hospital, Wolverhampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"key\n\t\t\t\t2018112010225032400_key217-B1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/BOR.0b013e3283524b82","article-title":"Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?","volume":"24","author":"Kiltz","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B3","author":"National Ankylosing Spondylitis Society"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/rheumatology\/kew223","article-title":"BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics","volume":"56","author":"Hamilton","year":"2016","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B5","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B6","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s10067-015-2913-2","article-title":"Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis","volume":"34","author":"Liang","year":"2015","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B7","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-eular.2087","article-title":"Is group-based exercise better than home-based exercise in patients with ankylosing spondylitis stabilized with tumor necrosis factor-alpha inhibitor therapy? A randomized controlled study","volume":"74","author":"Sollini","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B8","article-title":"Physiotherapy interventions for ankylosing spondylitis","volume":"1","author":"Dagfinrud","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/03009740500428806","article-title":"The effect of balneotherapy on patients with ankylosing spondylitis","volume":"35","author":"Altan","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B10","article-title":"Self management programme for ankylosing spondylitis","volume":"12","author":"Spencer","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.23275","article-title":"Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs","volume":"58","author":"Song","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1759720X12468658","article-title":"Axial spondyloarthritis: is there a treatment of choice?","volume":"5","author":"Poddubnyy","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B16","first-page":"1805","article-title":"Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis","volume":"33","author":"Barkhuizen","year":"2006","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1136\/ard.2008.092213","article-title":"MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib","volume":"68","author":"Jarrett","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B19","first-page":"60","article-title":"Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone","volume":"5","author":"Boersma","year":"1976","journal-title":"Scand J Rheumatol"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B20","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B22","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)","volume":"17","author":"Kroon","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B23","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.1016\/S0002-9343(98)00276-9","article-title":"Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus","volume":"105(5 Suppl 1)","author":"Bjorkman","year":"1998","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B25","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1016\/S0002-9343(00)00699-9","article-title":"Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors","volume":"110(Suppl 3A)","author":"Whelton","year":"2001","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B26","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis","volume":"96","author":"Goldstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B27","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B28","author":"FDA","year":"1996"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B29","doi-asserted-by":"crossref","first-page":"e000397","DOI":"10.1136\/rmdopen-2016-000397","article-title":"Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Regel","year":"2017","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B30","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B31","author":"FDA"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B32","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/ket450","article-title":"Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study","volume":"53","author":"Fagerli","year":"2014","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/ard.2006.052878","article-title":"Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B34","article-title":"Sulfasalazine for ankylosing spondylitis","volume":"27","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B37","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B38","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B39","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B40","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B41","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B42","first-page":"S1","article-title":"Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus naproxen vs naproxen alone: results from the infliximab as first line therapy in patients with early, active axial spondyloarthritis trial, part I","volume":"64","author":"Sieper","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B43","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B44","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B45"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B46","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B47","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B48","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study","volume":"41","author":"Breban","year":"2002","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B49","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","article-title":"Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST part 2","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B50","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B51","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B53","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B54","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B55","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B56","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/annrheumdis-2013-203425","article-title":"Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B57","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1136\/annrheumdis-2012-201914","article-title":"Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review","volume":"71","author":"van der Burg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B58","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tips.2008.11.004","article-title":"Interleukin-17 as a drug target in human disease","volume":"30","author":"Ivanov","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0091-6749(00)90189-1","article-title":"Increased elastase and myeloperoxidase activity associated with neutrophil recruitment by IL-17 in airways in vivo","volume":"105","author":"Hoshino","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/thx.2003.008854","article-title":"Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17 in mouse airways","volume":"59","author":"Prause","year":"2004","journal-title":"Thorax"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B62","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1165\/rcmb.2006-0020OC","article-title":"Functional relevance of the IL-23-IL-17 axis in lungs in vivo","volume":"36","author":"Ivanov","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B63","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B64","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B65"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B66","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B67","first-page":"S972","article-title":"Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging","volume":"63","author":"Baraliakos","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B68","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B69","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010225032400_key217-B71","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/suppl_6\/vi10\/26660384\/key217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T23:16:51Z","timestamp":1720394211000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/suppl_6\/vi10\/5184859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":71,"journal-issue":{"issue":"suppl_6","published-online":{"date-parts":[[2018,11,16]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key217","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,11,1]]}}}